Since my clients and colleagues have been remarkably gracious about my attempts to vacation this week, I will keep this brief and return to my rest BEvERage novel kids. Here’s some of what has been going on in my absence:
- Some fairly significant deal activity, especially for the end of August. Biovail picked up product rights from Swiss company Santhera, and Cardiome decided to use $27.5 million to buy back shares instead of to perform R&D.
- Some further good vibes for biotech investing, with more industry journalists picking up the meme, and rumours of new IPOs.